Reassessing Benefits and Risks of Hormone Therapy

American Journal of Lifestyle Medicine

Volumn 3, Issue 1, 2009, Pages 29-43

  Gass, Margery L S ^a   Bassuk, Shari S ^b   Manson, Joann E ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

age; estrogen; hormone therapy; progestogen; risk

Indexed keywords

EID: 78650788638     PISSN: 15598276     EISSN: None     Source Type: Journal    
DOI: 10.1177/1559827608323216     Document Type: Review

References (113)

1. Wilson RA Feminine Forever. New York: Evans (with Lippincott); 1966.
2. Smith DC, Prentice R., Thompson DJ, Herrmann WL Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975; 293: 1164-1167.
3. Ziel HK, Finkle WD Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975; 293: 1167-1170.
4. Weiss NS, Szekely DR, Austin DF Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976; 294: 1259-1262.
5. Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 1980; 55: 732-738.
6. Wilson PWF, Garrison RJ, Castelli WP Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med. 1985; 313: 1038-1043.
7. Stampfer MJ, Willett WC, Colditz GA, Rosner B., Speizer FE, Hennekens CH A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985; 313: 1044-1049.
8. Bush TL, Barrett-Connor E., Cowan LD, et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987; 75: 1102-1109.
9. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995; 273: 199-208.
10. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-613.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
12. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297: 1465-1477.
13. Grady D., Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117: 1016-1037.
14. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002; 288: 2123-2129.
15. Smith W., Mitchell P., Wang JJ Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997; 25(suppl 1):S13-S15.
16. Grodstein F., Colditz GA, Stampfer MJ Tooth loss and hormone use in postmenopausal women. Compend Contin Educ Dent Suppl. 1998;22: S9-S16.
17. Shah MG, Maibach HI Estrogen and skin: an overview. Am J Clin Dermatol. 2001; 2: 143-150.
18. Moehrer B., Hextall A., Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003;(2):CD001405.
19. Schiff I., Regestein Q., Tulchinsky D., Ryan KJ Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA. 1979; 242: 2405-2404.
20. Hersh AL, Stefanick ML, Stafford RS National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291: 47-53.
21. Hing E., Brett KM Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol. 2006; 108: 33-40.
22. Anderson GL, Limacher M., Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712.
23. Stefanick ML, Cochrane BB, Hsia J., Barad DH, Liu JH, Johnson SR The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003; 13: S78-S86.
24. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47: 1175-1187.
25. Bonds DE, Lasser N., Qi L., et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia. 2006; 49: 459-468.
26. North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause. 2007; 14: 168-182.
27. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006; 85: 155-160.
28. Albright F., Smith PH, Richardson AMJ. Postmenopausal osteoporosis. JAMA. 1941; 116: 2465-2477.
29. Lindsay R., Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976; 1: 1038-1041.
30. Quigley ME, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol. 1987; 156: 1516-1523.
31. Christiansen C., Riis BJ 17β-Estradiol and continuous norethisterone: a unique treatment of established osteoporosis in elderly women. J Clin Endocrinol Metab. 1990; 71: 836-841.
32. Recker RR, Davies KM, Dowd RM, Heaney RP The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med. 1999; 130: 897-904.
33. Ettinger B., Ensrud KE, Wallace R., et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004; 104: 443-451.
34. Wells G., Tugwell P., Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis: V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 23: 529-539.
35. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA. 1996; 276: 1389-1396.
36. Cauley JA, Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290: 1729-1738.
37. Torgerson DJ, Bell-Syer SE Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA. 2001; 285: 2891-2897.
38. Grady D., Cummings SR Postmenopausal hormone therapy for prevention of fractures: how good is the evidence? JAMA. 2001; 285: 2909-2910.
39. Siris ES, Miller PD, Barrett-Connor E., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286: 2815-2822.
40. Banks E., Beral V., Reeves G., Balkwill A., Barnes I., Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA. 2004; 291: 2212-2220.
41. Jackson RD, Wactawski-Wende J., LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006; 21: 817-828.
42. Miller J., Chan BK, Nelson HD Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 136: 680-690.
43. Grodstein F., Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996; 348: 983-987.
44. Grady D., Wenger NK, Herrington D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med. 2000; 132: 689-696.
45. Cushman M., Kuller LH, Prentice R., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292: 1573-1580.
46. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006; 166: 772-780.
47. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med. 1986;314: 1615-1620.
48. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation. 2007; 115: 840-845.
49. Straczek C., Oger E., Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112: 3495-3500.
50. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004; 292: 1581-1587.
51. Jick H., Derby LE, Myers MW, Vasilakis C., Newton KM Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348: 981-983.
52. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991; 133: 32-37.
53. Pickar JH, Yeh I., Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001; 76: 25-31.
54. Genant HK, Lucas J., Weiss S., et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/ Osteoporosis Study Group. Arch Intern Med. 1997; 157: 2609-2615.
55. Sturdee DW Endometrial safety and bleeding with HRT: what's new? Climacteric. 2007; 10(suppl 2):66-70.
56. Grodstein F., Colditz GA, Stampfer MJ Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994; 83: 5-11.
57. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2001; 135: 493-501.
58. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
59. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330-339.
60. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350: 1047-1059.
61. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003; 289: 3243-3253.
62. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006; 295: 1647-1657.
63. Porch JV, Lee IM, Cook NR, Rexrode KM, Buring JE Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002; 13: 847-854.
64. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006; 166: 1027-1032.
65. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol. 2002; 100: 1148-1158.
66. Grodstein F., Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000; 133: 933-941.
67. Grodstein F., Clarkson TB, Manson JE Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003; 348: 645-650.
68. Mendelsohn ME, Karas RH Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308: 1583-1587.
69. Chae CU, Manson JE Postmenopausal hormone therapy. In: Manson JE, Buring JE, Ridker PM, Gaziano JM, eds. Clinical Trials in Heart Disease. Philadelphia: WB Saunders; 2004.
70. Lobo RA, Bush T., Carr BR, Pickar JH Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001; 76: 13-24.
71. Clarkson TB Progestogens and cardiovascular disease: a critical review. J Reprod Med. 1999; 44: 180-184.
72. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids. 2000; 65: 651-658.
73. Mikkola TS, Clarkson TB Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002; 53: 605-619.
74. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000; 343: 522-529.
75. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;340: 535-545.
76. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 135: 939-953.
77. Hsia J., Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006; 166: 357-365.
78. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356: 2591-2602.
79. Grodstein F., Manson JE, Stampfer MJ Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006; 15: 35.
80. Salpeter SR, Walsh JME, Greyber E., Salpeter EE Brief report: coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med. 2006; 21: 363-366.
81. Harman SM, Brinton EA, Cedars M., et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005; 8: 3-12.
82. Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth WTJ. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med. 2002; 162: 1954-1960.
83. Wassertheil-Smoller S., Hendrix SL, Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative. A randomized trial. JAMA. 2003; 289: 2673-2684.
84. Hendrix SL, Wassertheil-Smoller S., Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006; 113: 2425-2434.
85. Kanaya AM, Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/ progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138:1-9.
86. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol. 1992; 2: 665-673.
87. Grodstein F., Newcomb PA, Stampfer MJ Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999; 106: 574-582.
88. Grodstein F., Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998; 128: 705-712.
89. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CWJ. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995; 87: 517-523.
90. Chlebowski RT, Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350: 991-1004.
91. Lacey JV Jr, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst. 2006;98: 1397-1405.
92. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003; 290: 1739-1748.
93. Henderson VW Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med. 1997; 103: 11S-18S.
94. Suzuki S., Gerhold LM, Bottner M., et al. Estradiol enhances neurogenesis following ischemic stroke through estrogen receptors alpha and beta. J Comp Neurol. 2007; 500: 1064-1075.
95. Hogervorst E., Williams J., Budge M., Riedel W., Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000; 101: 485-512.
96. LeBlanc ES, Janowsky J., Chan BK, Nelson HD Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001; 285: 1489-1499.
97. Nelson HD, Humphrey LL, Nygren P., Teutsch SM, Allan JD Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288: 872-881.
98. Henderson VW, Paganini-Hill A., Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000; 54: 295-301.
99. Mulnard RA, Cotman CW, Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000; 283: 1007-1015.
100. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54: 2061-2066.
101. Matthews K., Cauley J., Yaffe K., Zmuda JM Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc. 1999; 47: 518-523.
102. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006; 13: 28-36.
103. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57.
104. Shumaker SA, Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291: 2947-2958.
105. Gold EB, Sternfeld B., Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ ethnic population of women 40-55 years of age. Am J Epidemiol. 2000; 152: 463-473.
106. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology. 2007; 69: 1322-1330.
107. Salpeter SR, Walsh JM, Greyber E., Ormiston TM, Salpeter EE Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004; 19: 791-804.
108. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after stopping estrogen plus progestin in the Women's Health Initiative. JAMA. 2005; 294: 183-193.
109. Hays J., Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003; 348: 1839-1854.
110. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005; 105: 1063-1073.
111. Brunner RL, Gass M., Aragaki A., et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch Intern Med. 2005; 165: 1976-1986.
112. Weisberg E., Ayton R., Darling G., et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005; 8: 83-92.
113. Cicinelli E., Di Naro E., De Ziegler D., et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am J Obstet Gynecol. 2003; 189: 55-58.